|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Rikshospitalet University Hospital |
|---|---|
| Collaborator: |
GlaxoSmithKline |
| Information provided by: | Rikshospitalet University Hospital |
| ClinicalTrials.gov Identifier: | NCT00460070 |
Purpose
Some antiepileptic drugs are found to have hormonal side effects. We want to study possible hormonal side effects of the relatively new antiepileptic drug; levetiracetam and compare it to the older drugs; lamotrigine and carbamazepine. The participants are going to fill in a questionnaire and we will collect blood samples from them, to analyse hormones.
| Condition |
|---|
|
Epilepsy |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Cross-Sectional |
| Official Title: | Levetiracetam, Carbamazepine and Lamotrigine and Hormonal Side Effects in Adult Males and Females. |
| Enrollment: | 240 |
| Study Start Date: | January 2007 |
| Study Completion Date: | March 2009 |
We have previously performed long-term studies of rats treated with levetiracetam and compared them with a control group. Here we have found that levetiracetam has a probable effect on the ovaries, since the treated animals had larger ovaries, fewer cysts, more corpora lutea and more secondary follicles than the untreated animals (Taubøll et al 2004). Blood tests on the animals showed that those treated with levetiracetam had higher testosterone levels and lower levels of estrogen and FSH, whilst LH and progesterone levels were unaffected by the treatment (Svalheim et al, 2005a, b). Studies on cell cultures from pig ovaries, as carried out by our group in collaboration with Jagiellonian University, Krakow, Poland, appeared to support these findings (Taubøll et al. 2006, submitted).
Our wish therefore now is to study fertile men and women in order to look for any changes in the balance of sex hormones during use of levetiracetam in order to establish whether the findings in animal trials are clinically relevant to humans.
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Patients from the outpatients clinic
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Norway | |
| Dep. of Neurology, Rikshospitalet Universty Hospital | |
| Oslo, Norway, 0027 | |
| Principal Investigator: | Erik Taubøll, MD | unaffiliation |
More Information
| Responsible Party: | Erik Taubøll, Professor, Dep of Neurology, Rikshospitalet, OSLO |
| ClinicalTrials.gov Identifier: | NCT00460070 History of Changes |
| Other Study ID Numbers: | M52332 |
| Study First Received: | April 12, 2007 |
| Last Updated: | July 26, 2011 |
| Health Authority: | Norway: The National Committees for Research Ethics in Norway |
|
Epilepsy Brain Diseases Central Nervous System Diseases Nervous System Diseases Carbamazepine Lamotrigine Etiracetam Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions |
Central Nervous System Agents Therapeutic Uses Anticonvulsants Antimanic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Calcium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Cardiovascular Agents Nootropic Agents |